Clinical Trials
24 trialsLUPARPED
Fundación de investigación HM
Diagnosis of Pheochromocytoma
National Institutes of Health Clinical Center (CC)
Natural History Study of Children and Adults With Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
NET-COMPARE
British Columbia Cancer Agency
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Memorial Sloan Kettering Cancer Center
MK-6482-015
Merck Sharp & Dohme LLC
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
National Institutes of Health Clinical Center (CC)
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Perspective Therapeutics
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
National Cancer Institute (NCI)
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
Adrenal Tumors - Pathogenesis and Therapy
University of Wuerzburg
Project: Every Child for Younger Patients With Cancer
Children's Oncology Group
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
St. Jude Children's Research Hospital
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
National Institutes of Health Clinical Center (CC)
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Institutes of Health Clinical Center (CC)
PRRT-PGL-PHEO
Azienda USL Reggio Emilia - IRCCS
SJFAMILY
St. Jude Children's Research Hospital
Prospective Cohort Study of Pheochromocytoma/Paraganglioma
Peking Union Medical College Hospital
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
National Institutes of Health Clinical Center (CC)
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
National Institutes of Health Clinical Center (CC)